Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/222332
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Repurposing zileuton as a depression drug using an AI and in vitro approach

AutorKubick, Norwin; Pajares, Marta CSIC; Enache, Ioana; Manda, Gina; Mickael, Michel-Edwar
Palabras claveDepression
Macrophages
NRF2
Text mining
Deep neural network
AI
Fecha de publicación2020
EditorMultidisciplinary Digital Publishing Institute
CitaciónMolecules 25(9): 2155 (2020)
ResumenRepurposing drugs to target M1 macrophages inflammatory response in depression constitutes a bright alternative for commonly used antidepressants. Depression is a significant type of mood disorder, where patients suffer from pathological disturbances associated with a proinflammatory M1 macrophage phenotype. Presently, the most commonly used antidepressants such as Zoloft and Citalopram can reduce inflammation, but suffer from dangerous side effects without offering specificity toward macrophages. We employed a new strategy for drug repurposing based on the integration of RNA-seq analysis and text mining using deep neural networks. Our system employs a Google semantic AI universal encoder to compute sentences embedding. Sentences similarity is calculated using a sorting function to identify drug compounds. Then sentence relevance is computed using a custom-built convolution differential network. Our system highlighted the NRF2 pathway as a critical drug target to reprogram M1 macrophage response toward an anti-inflammatory profile (M2). Using our approach, we were also able to predict that lipoxygenase inhibitor drug zileuton could modulate NRF2 pathway in vitro. Taken together, our results indicate that reorienting zileuton usage to modulate M1 macrophages could be a novel and safer therapeutic option for treating depression.
DescripciónThis article belongs to the Special Issue AI in Drug Design.
Versión del editorhttps://doi.org/10.3390/molecules25092155
URIhttp://hdl.handle.net/10261/222332
DOI10.3390/molecules25092155
E-ISSN1420-3049
Aparece en las colecciones: (IIBM) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
repurappro.pdf3,2 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

6
checked on 27-mar-2024

SCOPUSTM   
Citations

9
checked on 28-mar-2024

WEB OF SCIENCETM
Citations

8
checked on 28-feb-2024

Page view(s)

129
checked on 29-mar-2024

Download(s)

231
checked on 29-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons